According to @gdb (Greg Brockman) referencing @sebkrier, a report from The Australian details how tech executive Paul Conyngham used AI tools, including ChatGPT, to help design a custom mRNA vaccine that put his dog’s cancer into remission, marking what the article calls the first personalized cancer vaccine designed for a dog. According to The Australian, Conyngham leveraged AI-assisted literature review, target epitope selection, and sequence design workflows to rapidly prototype a bespoke mRNA construct, then partnered with contract labs for synthesis and veterinary oversight, compressing timelines and costs typically associated with oncology R&D. As reported by The Australian, the case underscores emerging commercial opportunities for AI-guided neoantigen discovery, low-volume GMP manufacturing, and veterinary oncology platforms that offer precision immunotherapy for pets, while raising regulatory and safety considerations for off-label and experimental use. According to The Australian, the workflow combined conversational AI for protocol drafting with bioinformatics-style sequence design, offering a template for startups to productize AI copilots for mRNA vaccine design, quality control checklists, and lab-to-clinic orchestration in the veterinary market.

According to The Rundown AI, an AI consultant without formal biology training used ChatGPT and AlphaFold to design a personalized mRNA cancer vaccine for his rescue dog, leading to a reported 50 percent tumor reduction; UNSW structural biologist Dr. Kate Michie called it encouraging that a non-scientist could execute such a pipeline. As reported by The Rundown AI, the workflow combined large language model-assisted peptide selection with AlphaFold structure predictions to inform neoantigen design, culminating in a custom mRNA formulation. According to The Rundown AI, while this is a single anecdotal outcome and not clinical evidence, it highlights emerging opportunities for AI-enabled neoantigen discovery tools, LLM copilots for wet-lab design, and contract manufacturing platforms offering rapid mRNA vaccine turnaround for veterinary oncology.